999. Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV incidence: Results from the DISCOVER trial

BACKGROUND: RRandomized trials of new PrEP agents compare to oral emtricitabine+tenofovir disoproxil fumarate (F/TDF) and do not have a placebo arm. We used the well-characterized adherence-efficacy relationship for F/TDF from iPrEX OLE, to back-calculate the (non-PrEP) background HIV incidence (bHI...

Descripción completa

Detalles Bibliográficos
Autores principales: Glidden, David V, Dunn, David T, Das, Moupali, Ebrahimi, Ramin, Zhong, Lijie, Stirrup, Oliver T, Anderson, Peter L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776424/
http://dx.doi.org/10.1093/ofid/ofaa439.1185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776424/
http://dx.doi.org/10.1093/ofid/ofaa439.1185

Ejemplares similares